2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Plus…
amazon.de The Cotswold Library Gebraucht, wie neu. Frais d'envoiAuf Lager. Die angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00) Details... |
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Plus…
amazon.de Frais d'envoiDie angegebenen Versandkosten können von den tatsächlichen Kosten abweichen. (EUR 3.00) Details... |
2012, ISBN: 3642282954
2012 Gebundene Ausgabe Krebs (Krankheit), Tumor / Krebs, MitogenActivatedProteinKinase(MAPK); Rafkinases; Biomarkers; chemicallibrary; clinicaltrialdesign; drugdevelopment; drugefficacy… Plus…
Achtung-Buecher.de MARZIES.de Buch- und Medienhandel, 14621 Schönwalde-Glien Frais d'envoiVersandkostenfrei innerhalb der BRD. (EUR 0.00) Details... |
2012, ISBN: 9783642282959
[PU: Springer Berlin], Buchschnitt verkürzt - gepflegter, sauberer Zustand - 2012 Ausgabejahr 11863221/12, DE, [SC: 0.00], gebraucht; sehr gut, gewerbliches Angebot, 2012, PayPal, Klarna-… Plus…
booklooker.de |
2012, ISBN: 9783642282959
Buch, Hardcover, 2012, [PU: Springer Berlin], Springer Berlin, 2012
lehmanns.de Frais d'envoisofort lieferbar. (EUR 0.00) Details... |
Therapeutic Kinase Inhibitors (Current Topics in Microbiology and Immunology, 355, Band 355) - edition reliée, livre de poche
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Plus…
2012, ISBN: 9783642282959
Springer, Gebundene Ausgabe, Auflage: 2012, 244 Seiten, Publiziert: 2012-03-22T00:00:01Z, Produktgruppe: Buch, Hersteller-Nr.: 8 black & white tables, biography, 1.18 kg, Rechtsmedizin, M… Plus…
2012
ISBN: 3642282954
2012 Gebundene Ausgabe Krebs (Krankheit), Tumor / Krebs, MitogenActivatedProteinKinase(MAPK); Rafkinases; Biomarkers; chemicallibrary; clinicaltrialdesign; drugdevelopment; drugefficacy… Plus…
2012, ISBN: 9783642282959
[PU: Springer Berlin], Buchschnitt verkürzt - gepflegter, sauberer Zustand - 2012 Ausgabejahr 11863221/12, DE, [SC: 0.00], gebraucht; sehr gut, gewerbliches Angebot, 2012, PayPal, Klarna-… Plus…
2012, ISBN: 9783642282959
Buch, Hardcover, 2012, [PU: Springer Berlin], Springer Berlin, 2012
Données bibliographiques du meilleur livre correspondant
Informations détaillées sur le livre - Therapeutic Kinase Inhibitors (Current Topics in Microbiology and Immunology, 355, Band 355)
EAN (ISBN-13): 9783642282959
ISBN (ISBN-10): 3642282954
Version reliée
Date de parution: 2012
Editeur: Mellinghoff, Ingo K. Sawyers, Charles L. Springer
234 Pages
Poids: 0,492 kg
Langue: Englisch
Livre dans la base de données depuis 2007-02-22T17:09:48+01:00 (Paris)
Page de détail modifiée en dernier sur 2023-06-06T14:17:49+02:00 (Paris)
ISBN/EAN: 3642282954
ISBN - Autres types d'écriture:
3-642-28295-4, 978-3-642-28295-9
Autres types d'écriture et termes associés:
Auteur du livre: mell, sawyer, mellin, melling
Titre du livre: kina kina, ingo, microbiology
Données de l'éditeur
Auteur: Ingo K. Mellinghoff; Charles L. Sawyers
Titre: Current Topics in Microbiology and Immunology; Therapeutic Kinase Inhibitors
Editeur: Springer; Springer Berlin
234 Pages
Date de parution: 2012-03-22
Berlin; Heidelberg; DE
Imprimé / Fabriqué en
Langue: Anglais
160,49 € (DE)
164,99 € (AT)
177,00 CHF (CH)
POD
X, 234 p.
BB; Hardcover, Softcover / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Medizin, Gesundheit; Mitogen Activated Protein Kinase (MAPK); Raf kinases; biomarkers; chemical library; clinical trial design; drug development; drug efficacy; epigenetics; gastrointestinal stromal tumor (GIST); genetically engineered mouse models (GEMMs); glioblastoma; lung adenocarcinoma; lung cancer; melanoma; myeloproliferative neoplasms; small molecules; Cancer Biology; EA; BC
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert.
Includes supplementary material: sn.pub/extras
Autres livres qui pourraient ressembler au livre recherché:
Dernier livre similaire:
9783642445804 Therapeutic Kinase Inhibitors (Sawyers, Charles L. (Herausgeber); Mellinghoff, Ingo K. (Herausgeber))
< pour archiver...